Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AsiDNA + Olaparib in Recurrent Solid Tumors
NCT05700669Phase 2Completed
- Sponsor
- Valerio Therapeutics
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label trial of asidna in ovarian epithelial cancer, breast cancer and metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Valerio Therapeutics. Primary endpoints: Safety and Tolerability (AEs, SAEs, DLTs), Recommended Phase 2 Dose and 1 more. Started Feb 2023; status: completed.
02
Drugs
asidna
03
Conditions
ovarian epithelial cancerbreast cancermetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05700669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700669.